Bayer stock edges lower as Roundup settlement test and new cancer drug approval shape outlook

Published on 09/12/2026 at 14:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock closed at EUR 48.17 on Xetra on September 11, 2026, about 31 percent below the EUR 70 analyst high target cited in recent coverage. Deutsche Bank keeps Bayer stock rated Buy with a EUR 60 target as of September 10, 2026, while legal risks remain in focus.

Flatlay auf weißem Untergrund: weiße runde Tabletten, Marmorstößel, grünes Pflanzenblatt, Glasflakon und gedrucktes DNA-Doppelhelix-Diagramm; Beschriftungskarte mit Text PHARMA — Top-down-Arrangement: weiße Tabletten, Mörser, grünes Blatt, DNA-Diagramm, Beschriftungskarte PHARMA, Illustration mit AI erstellt.

Bayer stock (ISIN DE000BAY0017) closed at EUR 48.17 on Xetra on September 11, 2026, down 1.09 percent from the prior close and trading well below recent analyst price targets that reach up to EUR 70.

Analysts maintain Buy ratings despite legal overhang

According to Yahoo Finance, Bayer stock on Xetra closed at EUR 48.17 on September 11, 2026, after falling 1.09 percent on the day, with analyst price targets ranging from EUR 46 to a high of EUR 70 and an average around EUR 58.22.

Deutsche Bank Research reaffirmed its Buy rating on Bayer with a price target of EUR 60 in a note dated September 10, 2026, when the shares were trading around EUR 48.12, implying upside of roughly 24.7 percent from that level, as reported by finanzen.at.

Barclays recently raised its price target on Bayer from EUR 60 to EUR 70 while reiterating an Overweight rating, signaling that some analysts see scope for a re-rating if operational progress continues, as highlighted by Ad-hoc-news.

Roundup settlement faces pivotal court test

As Investing.com reports on September 11, 2026, Bayer is heading into a pivotal court hearing in Missouri that will test the company's proposed USD 7.25 billion settlement framework for Roundup-related litigation, with proceedings expected to run into late 2026.

The legal case represents a key risk factor for Bayer shareholders, because a failure to secure court approval for the settlement could prolong uncertainty and potentially lead to higher costs, while a successful resolution would reduce a major overhang that has weighed on the stock in recent years, according to the assessment outlined by Investing.com.

In parallel, Ad-hoc-news notes that Bayer stock around EUR 48.80 on Xetra as of September 10, 2026, reflected a mixed reaction to the combination of regulatory progress and legal uncertainty, as investors weighed the potential earnings contribution of approved drugs against the scale of litigation provisions.

New cancer drug approval adds to growth pipeline

Bayer's long-term growth story is being underpinned by its pharmaceutical pipeline, where a notable recent development has been the United States Food and Drug Administration's accelerated approval of HYRNUO (sevabertinib) as a first-line targeted therapy for patients with HER2-mutated non-small cell lung cancer, announced on September 9, 2026, according to MarketBeat.

The accelerated approval in this niche oncology indication is expected to support Bayer's specialty medicine revenue base over coming years, even though precise sales guidance has not been detailed in the snippets, and it contributes to a broader perception among analysts that Bayer's drug pipeline can help offset pressure from its crop science business and legacy legal issues, as reflected in the Buy consensus described by MarketBeat.

MarketBeat indicates that Bayer has received an average analyst rating of Buy with an average rating score of 3.13, based on 2 strong buy, 5 buy and 1 hold recommendations, underscoring that the majority of covering analysts remain constructive on the shares despite the volatile backdrop.

Stock trades below analyst targets as investors weigh risk and reward

With Bayer stock at EUR 48.17 on Xetra as of September 11, 2026, the shares are trading about 15.5 percent below the average analyst target of EUR 58.22 reported by Yahoo Finance and around 31 percent below the high target of EUR 70 cited in the same overview.

This gap between the current market price and analyst valuations illustrates the market's caution around the Roundup settlement process and other litigation, but it also highlights the potential re-rating room if Bayer manages to secure court approval for its USD 7.25 billion settlement framework and delivers on the earnings contribution from new therapies such as HYRNUO, based on the scenarios discussed by Investing.com.

Current price and trading data

Per Xetra data summarized by Yahoo Finance, Bayer stock closed at EUR 48.17 on Xetra on September 11, 2026, compared with a previous close of EUR 48.70, with the one-year return figure in the quote overview indicating a strongly positive performance over the past 12 months even after the recent pullback.